MHRAsafety guidance72% confidence
ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Novartis.
Regulatory Analysis
Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-mediated angioedema does not respond to standard treatment.
Supporting Context
- Therapeutic area
- Oncology · Pediatric
- Sub-indication
- Ild
Related signal: Feasibility Study on Sensory Changes in Pediatric Oncology Patients Undergoing Treatment